RADIATION THERAPY ONCOLOGY GROUP
RTOG 0435
A RANDOMIZED, PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALIFERMIN (NSC# 740548; IND #6370) FOR THE REDUCTION OF ORAL MUCOSITIS IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER RECEIVING RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY (FOLLOWED BY SURGERY FOR SELECTED PATIENTS)
RTOG 0435
A RANDOMIZED, PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALIFERMIN (NSC# 740548; IND #6370) FOR THE REDUCTION OF ORAL MUCOSITIS IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER RECEIVING RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY (FOLLOWED BY SURGERY FOR SELECTED PATIENTS)
Protocol Participation Information
- Credentialing
- Credentialing Requirements
- Facility Questionnaire: 3DCRT, IMRT
- How to Participate
- Digital Data Submission Procedures
- Digital Data Submission Information (DDSI) Form
- Submission Check list
- ATC Compliant Treatment Planning Systems
- QA Guidelines (IMRT)
- Neck Node Atlas
- Protocol Text (http://www.rtog.org/)
Back to protocols
